Skip to content

10x Genomics, Inc. TXG Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$490.29M+30.0%$473.97M+37.8%$432.71M+8.7%$397.71M+4.7%$377.06M+6.0%
$49.56M-0.6%$49.44M+0.2%$49.58M$49.55M+18,320%$49.84M+211%
$39.03M-25.7%$47.01M-46.5%$43.78M-47.6%$49.98M-45.2%$52.55M-42.4%
$53.49M-28.4%$56.34M-32.2%$61.96M-34.1%$68.97M-21.9%$74.71M-10.2%
$669.73M+15.5%$684.45M+17.1%$659.83M+11.1%$655.66M+13.2%$579.73M+2.2%
$220.59M-10.4%$226.71M-10.3%$232.53M-10.1%$239.71M-9.0%$246.09M-8.7%
$4.51M0.0%$4.51M0.0%$4.51M0.0%$4.51M0.0%$4.51M0.0%
$59.91M+294%$62.33M+298%$64.76M+301%$14.71M-11.7%$15.19M-5.8%
$1.02B+12.4%$1.04B+13.4%$1.03B+9.6%$979.97M+5.4%$903.39M-2.1%
$17.43M+73.1%$12.73M-1.4%$18.07M-31.1%$15.94M-25.0%$10.07M-50.2%
$24.34M+16.2%$23.9M+15.7%$22.14M+24.7%$21.45M+30.5%$20.95M+46.5%
$113.6M+5.3%$153.45M+30.5%$147.32M+21.5%$112.22M+1.1%$107.9M-0.8%
$201.44M+2.5%$245.04M+17.5%$242.24M+12.7%$206.69M+0.5%$196.5M-3.7%
$2K0.0%$2K0.0%$2K0.0%$2K0.0%$2K0.0%
-$1.52B-1.5%-$1.51B-3.0%-$1.49B-5.4%-$1.47B-6.1%-$1.5B-11.7%
$814.32M+15.2%$796.33M+12.1%$785.12M+8.6%$773.28M+6.8%$706.9M-1.7%
$1.02B+12.4%$1.04B+13.4%$1.03B+9.6%$979.97M+5.4%$903.39M-2.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are 10x Genomics, Inc.'s total assets?
10x Genomics, Inc. (TXG) holds $1.0B in total assets, up 12.4% year over year.
How much debt does 10x Genomics, Inc. have?
10x Genomics, Inc. carries $81.4M in total debt against $814.3M of shareholders' equity, a debt-to-equity ratio of 0.10.
How much cash does 10x Genomics, Inc. have?
10x Genomics, Inc. holds $490.3M in cash and equivalents.
Can 10x Genomics, Inc. cover its short-term obligations?
Its current ratio is 5.90 — current assets exceed current liabilities.
Where does 10x Genomics, Inc.'s balance sheet data come from?
Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.